# A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

> **NCT01334203** · PHASE4 · WITHDRAWN · sponsor: **Gilead Sciences**

## Conditions studied

- Angina Pectoris
- Coronary Artery Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ranolazine

## Key facts

- **NCT ID:** NCT01334203
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01334203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01334203, "A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01334203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*